Last reviewed · How we verify

flunarizine and/or pregabalin

Taipei Veterans General Hospital, Taiwan · FDA-approved active Small molecule Quality 51/100

flunarizine and/or pregabalin is a ["Calcium Channel Blocker", "Anticonvulsant"] Small molecule drug developed by Taipei Veterans General Hospital, Taiwan. It is currently FDA-approved.

Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters.

Flunarizine and pregabalin are both used for the management of neuropathic pain and other neurological conditions. Flunarizine is a calcium channel blocker primarily used for the prevention of migraines, while pregabalin is an anticonvulsant that is also effective in treating neuropathic pain. Both drugs have been studied at Taipei Veterans General Hospital, Taiwan, but they do not have FDA approval. Safety profiles include common side effects such as dizziness, somnolence, and peripheral edema. Commercially, pregabalin has seen significant revenue, while flunarizine's market presence is more limited.

At a glance

Generic nameflunarizine and/or pregabalin
SponsorTaipei Veterans General Hospital, Taiwan
Drug class["Calcium Channel Blocker", "Anticonvulsant"]
Target["L-type calcium channels", "alpha2-delta subunit of voltage-gated calcium channels"]
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Mechanism of action

Flunarizine works by blocking calcium channels, which helps to stabilize neuronal membranes and reduce the release of neurotransmitters involved in pain signaling. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, leading to a reduction in the release of excitatory neurotransmitters such as glutamate and substance P.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType
US6133320A2023
US4083870AExpired

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about flunarizine and/or pregabalin

What is flunarizine and/or pregabalin?

flunarizine and/or pregabalin is a ["Calcium Channel Blocker", "Anticonvulsant"] drug developed by Taipei Veterans General Hospital, Taiwan.

How does flunarizine and/or pregabalin work?

Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters.

Who makes flunarizine and/or pregabalin?

flunarizine and/or pregabalin is developed and marketed by Taipei Veterans General Hospital, Taiwan (see full Taipei Veterans General Hospital, Taiwan pipeline at /company/taipei-veterans-general-hospital-taiwan).

What drug class is flunarizine and/or pregabalin in?

flunarizine and/or pregabalin belongs to the ["Calcium Channel Blocker", "Anticonvulsant"] class. See all ["Calcium Channel Blocker", "Anticonvulsant"] drugs at /class/calcium-channel-blocker-anticonvulsant.

What development phase is flunarizine and/or pregabalin in?

flunarizine and/or pregabalin is FDA-approved (marketed).

What are the side effects of flunarizine and/or pregabalin?

Common side effects of flunarizine and/or pregabalin include Dizziness, Somnolence, Peripheral Edema, Weight Gain, Blurred Vision.

What does flunarizine and/or pregabalin target?

flunarizine and/or pregabalin targets ["L-type calcium channels", "alpha2-delta subunit of voltage-gated calcium channels"] and is a ["Calcium Channel Blocker", "Anticonvulsant"].

Related